Company profile
Calliditas Therapeutics
Renal/hepatic disease therapeutics
Subsidiary of Asahi Kasei Corporation (3407) · Sweden
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Budesonide (targeted-release)(TARPEYO / Nefecon) | Approved | Glucocorticoid receptorSmall molecule | Chronic Kidney DiseaseGlomerular Disease Primary IgA Nephropathy |
| Phase 2 | NOX1/4Small molecule | Cholestatic Liver Disease Primary Biliary Cholangitis |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.